Posted On: 09/15/2015 10:10:48 PM
Post# of 30015
![Avatar](https://investorshangout.com/images/ProfileImages/1996739806_13310_Entertained 3.jpg)
Quote:
With the Orphan Drug indications, we believe MANF is highly attractive to potential partners. The candidate could help AMBS negotiate a favorable terms with potential partners for non-dilutive funding for Phase I and Phase II clinical trials.
Quote:
We believe the up-list will act as a major catalyst to drive institutional awareness in the story, and that several pending catalysts over the next 15 months, including the AMDX sales / spin-off, starting human clinical trials with MANF , reporting results from the eltoprazine Phase IIb data, and the ESS Phase IIa data should allow for the realization of a significantly higher stock price.
http://scr.zacks.com/News/Press-Releases/Pres...fault.aspx
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)